Impax Laboratories v. Biocon: Carbidopa/Levodopa Patent Settlement in Landmark Hatch-Waxman Case
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Impax Laboratories, LLC v. Biocon Pharma Ltd. |
| Case Number | 2:25-cv-01968 |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Mar 2025 – Feb 2026 345 days |
| Outcome | Settlement — Terms Confidential |
| Patents at Issue | |
| Accused Products | Carbidopa and Levodopa Extended-Release Capsules |
Case Overview
The Parties
⚖️ Plaintiff
A specialty pharmaceutical company with a significant portfolio of branded and generic drug products, including formulations addressing neurological conditions.
🛡️ Defendant
A global biopharmaceutical company headquartered in India with an established presence in the U.S. generic drug market.
The Patents at Issue
This landmark case involved five U.S. patents covering formulation and dosing technologies related to extended-release delivery of carbidopa and levodopa, protecting multiple therapeutic dose strengths and release mechanisms that differentiate the branded product from conventional immediate-release formulations. These patents are registered with the U.S. Patent and Trademark Office (USPTO).
- • US8557283B2 — Extended-release carbidopa and levodopa capsule formulations
- • US9463246B2 — Methods of using extended-release carbidopa and levodopa capsules
- • US9089608B2 — Specific release profiles for carbidopa and levodopa formulations
- • US9533046B2 — Pharmaceutical compositions of carbidopa and levodopa
- • US9901640B2 — Dosing regimens for extended-release carbidopa and levodopa
Developing a generic drug?
Check if your pharmaceutical formulation might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The case was resolved through a voluntary dismissal without prejudice entered by stipulation of the parties under Fed. R. Civ. P. 41(a)(1)(A)(ii). The court retained jurisdiction to enforce the settlement agreement and the dismissal order. Specific financial terms, licensing arrangements, and any authorized entry dates for Biocon’s generic product were not publicly disclosed, which is standard practice in pharmaceutical patent settlements. No damages award was issued. No injunctive relief was formally granted or denied by the court. Resolution was achieved through a negotiated settlement agreement, the terms of which remain confidential.
Key Legal Issues
The underlying cause of action was patent infringement, consistent with Hatch-Waxman litigation triggered by an Abbreviated New Drug Application (ANDA) filing. Under the Hatch-Waxman framework, a generic manufacturer’s ANDA filing for a product covered by a listed patent constitutes a technical act of infringement, enabling the brand company to file suit and potentially invoke a 30-month regulatory stay preventing FDA approval during litigation.
With five patents asserted across multiple application families, Impax mounted a layered infringement claim covering different aspects of the extended-release formulation — a common prosecution and assertion strategy designed to create overlapping claim coverage that is difficult to design around. Biocon’s defense would have included invalidity challenges under 35 U.S.C. §§ 102 and 103 (anticipation and obviousness), non-infringement arguments based on claim construction, and potentially enablement or written description challenges under § 112.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical formulations. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation for pharma.
- View all related drug patents in this therapeutic space
- See which companies are most active in pharma formulation patents
- Understand claim construction patterns for extended-release drugs
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your generic drug or formulation.
- Input your drug description or technical features
- AI identifies potentially blocking drug patents
- Get actionable risk assessment report
High Risk Area
Extended-release formulations for carbidopa/levodopa
5 Related Patents
In carbidopa/levodopa formulation space
Design-Around Options
Available for some formulation claims
✅ Key Takeaways
Five-patent assertion across continuation families maximizes settlement leverage in ANDA litigation.
Search related case law →Voluntary dismissal without prejudice preserves future enforcement rights if settlement terms are violated.
Explore precedents →Frequently Asked Questions
Five U.S. patents were asserted: US8557283B2, US9463246B2, US9089608B2, US9533046B2, and US9901640B2, all covering carbidopa and levodopa extended-release capsule formulations.
The case was dismissed voluntarily by stipulation of the parties under Fed. R. Civ. P. 41(a)(1)(A)(ii), following a confidential settlement agreement. The dismissal was entered without prejudice, and the court retained jurisdiction to enforce the settlement.
It reinforces that multi-patent formulation portfolios remain effective assertion tools in ANDA litigation, and that pre-trial settlement is the dominant resolution pathway in pharmaceutical patent disputes.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- United States District Court for the District of New Jersey — Case 2:25-cv-01968
- U.S. Patent and Trademark Office — Patent Full-Text and Image Database
- FDA Orange Book — Approved Drug Products
- Cornell Legal Information Institute — 35 U.S.C. §§ 102, 103, 112
- PatSnap — IP Intelligence Solutions for Pharmaceutical Companies
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.